Although it is not known if these mechanisms are involved in relapse after anti-GPRC5D CAR T cell therapy, these studies highlight the complex nature of myeloma tumor biology and requirement of layered treatment strategies to thwart resistance. The gene discussed is GPRC5D; the disease is plasma cell myeloma.